Victoria, British Columbia, Canada, September 28, 2018 - IMMUNOPRECISE ANTIBODIES LTD.(“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by issuing a total of 9,102,500 units (“Units”) of ImmunoPrecise at a price of $1.00 per Unit for gross proceeds of $9,102,500 (the “Financing”).  Due to strong investor … Continue reading